From: Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Characteristic | No. of patients (%) |
---|---|
Mean age (standard deviation) | 57 years (14) |
Male sex | 54 (66) |
Race/ethnicity | |
White | 63 (77) |
Black | 7 (9) |
Hispanic | 9 (11) |
Other | 3 (4) |
Baseline risk factors | |
History of smoking | 35 (43) |
Alcohol consumption | 35 (43) |
Type II diabetes mellitus | 21 (26) |
Drug allergy | 51 (62) |
Prior history of pancreatitis | 7 (9) |
Pancreatic metastasis | 11 (13) |
Cancer type | |
Melanoma | 30 (37) |
Genitourinary | 24 (29) |
Lung, head and neck | 11 (13) |
Gastrointestinal | 5 (6) |
Other solid tumors | 5 (6) |
Hematologic malignancies | 7 (9) |
Cancer stagea | |
Stage III | 3 (4) |
Stage IV | 72 (96) |
Median number of immune checkpoint inhibitor doses (interquartile range) | 4 (1-25) |
Checkpoint inhibitor type | |
CTLA-4 monotherapy | 12 (15) |
PD-1/L1 monotherapy | 53 (65) |
Combination therapyb | 17 (21) |
Other immune-related adverse events | |
Gastrointestinal | 27 (33) |
Hepatic | 17 (21) |
Dermatologic | 13 (16) |
Endocrine | 7 (9) |
Pulmonary | 5 (6) |
Other | 6 (7) |